Novo Nordisk A/S (NVO)
127.29
+2.70
(+2.17%)
USD |
NYSE |
May 07, 16:00
128.60
+1.31
(+1.03%)
Pre-Market: 07:08
Novo Nordisk Research and Development Expense (Quarterly): 1.254B for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 1.254B |
December 31, 2023 | 1.510B |
September 30, 2023 | 1.187B |
June 30, 2023 | 1.042B |
March 31, 2023 | 970.27M |
December 31, 2022 | 1.111B |
September 30, 2022 | 762.61M |
June 30, 2022 | 733.41M |
March 31, 2022 | 785.33M |
December 31, 2021 | 866.26M |
September 30, 2021 | 674.11M |
June 30, 2021 | 639.17M |
March 31, 2021 | 639.35M |
December 31, 2020 | 718.12M |
September 30, 2020 | 614.39M |
June 30, 2020 | 486.02M |
March 31, 2020 | 557.60M |
December 31, 2019 | 649.91M |
September 30, 2019 | 536.43M |
June 30, 2019 | 535.14M |
March 31, 2019 | 407.57M |
December 31, 2018 | 694.69M |
September 30, 2018 | 568.25M |
June 30, 2018 | 528.13M |
March 31, 2018 | 547.88M |
Date | Value |
---|---|
December 31, 2017 | 630.23M |
September 30, 2017 | 525.94M |
June 30, 2017 | 504.80M |
March 31, 2017 | 471.18M |
December 31, 2016 | 648.16M |
September 30, 2016 | 518.52M |
June 30, 2016 | 505.69M |
March 31, 2016 | 488.49M |
December 31, 2015 | 591.57M |
September 30, 2015 | 489.80M |
June 30, 2015 | 449.39M |
March 31, 2015 | 492.25M |
December 31, 2014 | 648.56M |
September 30, 2014 | 649.75M |
June 30, 2014 | 565.08M |
March 31, 2014 | 581.56M |
December 31, 2013 | 650.72M |
September 30, 2013 | 496.71M |
June 30, 2013 | 475.60M |
March 31, 2013 | 470.21M |
December 31, 2012 | 558.17M |
September 30, 2012 | 439.34M |
June 30, 2012 | 442.56M |
March 31, 2012 | 442.05M |
December 31, 2011 | 498.30M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
486.02M
Minimum
Jun 2020
1.510B
Maximum
Dec 2023
813.57M
Average
725.76M
Median
Research and Development Expense (Quarterly) Benchmarks
Amgen Inc | 1.343B |
Vertex Pharmaceuticals Inc | 789.10M |
Viking Therapeutics Inc | 24.10M |
Evaxion Biotech AS | 2.298M |
Moderna Inc | 1.063B |